This study assessed the immunomodulatory effects in previously treated KRAS-mutant metastatic colorectal cancer patients participating in a phase II multicenter, open-label clinical trial receiving le
The purpose of this study is to cross-vaccinate and collect safety data in terms of unsolicited Adverse Events (AEs), Serious Adverse Events (SAEs) and potential Immune Mediated Disease (pIMD) from
Binding antibody multiplex assay (BAMA) and intracellular cytokine staining (ICS) data from HVTN 100, HVTN 097, and RV144. The posted data underlie the vaccine immunogenicity findings in the papers "L
